VentureBeat September 24, 2024
Louis Columbus

With all seven independent directors resigning from 23andMe last week, the company has become a cautionary tale of why cybersecurity is a business decision for any enterprise first, as there are immediate and lasting impacts to any organization ignoring that. Customers aren’t sure how the company plans to strengthen its security and protect their DNA and other confidential personally identifiable information (PII). Enterprises can’t afford to allow security to become a liability.

Multiple large-scale security breaches have jilted existing customers’ confidence and made potential customers think twice about sharing their DNA data with 23andMe.

The independent board members unanimously resigned in response to CEO Anne Wojcicki’s push to take the company private on Sept. 17. The resignation states that they...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Cybersecurity, Pharma / Biotech, Technology
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
Deep learning revolutionizes RNA 3D structure prediction with RhoFold+
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future

Share This Article